NRAS and cancer: Our studies identified NEK9 and CDK16 as two dabrafenib‐specific kinase targets and provide evidence that inhibition of NEK9 and CDK16 may underlie the greater effectiveness of this drug against NRAS‐ and KRAS‐mutant cancer cells.